Osteoarthritis Clinical Trials 2025: EMA, PDMA, FDA Approvals, Medication, Therapies, Treatment Market, Mechanism of Action, Route of Administration, and Companies by DelveInsight

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Osteoarthritis pipeline constitutes 100+ key companies continuously working towards developing 110+ Osteoarthritis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Osteoarthritis Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Osteoarthritis Market.

The Osteoarthritis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Request for Sample Report here @ https://www.delveinsight.com/report-store/osteoarthritis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Some of the key takeaways from the Osteoarthritis Pipeline Report:
• Osteoarthritis Companies across the globe are diligently working toward developing novel Osteoarthritis treatment therapies with a considerable amount of success over the years.
• Osteoarthritis companies working in the treatment market are Biosplice Therapeutics, Cynata Therapeutics, Bone Therapeutics S.A, Regeneron Pharmaceuticals, Techfields Pharma, Ampio Pharmaceuticals, Asahi Kasei Pharma, Taiwan Bio Therapeutics, OliPass Corporation, Bioventus, Medipost, LG Chem, ICM Biotech, Cells for Cells SA, GWOXI Stem Cell Applied Technology, UnicoCell Biomed, Magellan Biologicals, Levicept, Arthrogen, Personalized Stem Cells, Peptinov, Orient Europharma, ZYUS Life Sciences, Lubris Biopharma, Saol Therapeutics, Ageless Biotech, Synartro AB, Plakous Therapeutics, Ribomic, Meluha Therapeutics, and others, are developing therapies for the Osteoarthritis treatment
• Emerging Osteoarthritis therapies such as Lorecivivint, EP-104IAR, DFV890, 4P004, GNSC 001, and others are expected to have a significant impact on the Osteoarthritis market in the coming years.
• In May 2025, Hyalex Orthopaedics, a privately held medical device company developing joint preservation technologies based on the transformative HYALEX® HYDROSURF materials platform, today announced that the U.S. Food and Drug Administration (FDA) has approved the company's supplemental Investigational Device Exemption (IDE) application for its cutting-edge Freestyle Knee Implant. This approval paves the way for Hyalex to expand its Early Feasibility Study (EFS) into a pivotal clinical trial of its novel knee implant technology, supporting the company's continued efforts to bring this next-generation orthopedic solution to patients in need. Company Plans to Initiate Pivotal Study of Transformative Implant Technology Designed to Help Patients with Cartilage Damage and Early Osteoarthritis Regain an Active Lifestyle.
• In March 2025, Lipogems has announced the final patient enrolled in the ARISE II U.S. FDA IDE Study, which aims to evaluate the efficacy and safety of MicroFat injections compared to saline for the treatment of Knee Osteoarthritis (OA). The double blinded, randomized, controlled trial enrolled 173 subjects in 9 months across 16 well-respected U.S. sites. The primary endpoints evaluate improvement in pain and function at 6 months post-injection. Efficacy and safety results from ARISE II are expected to be announced in late 2025.
• In February 2025, Zydus Lifesciences (NSE: ZYDUSLIFE) received final approval from the U.S. Food and Drug Administration (FDA) to produce Ibuprofen and Famotidine tablets (800 mg/26.6 mg), marketed under the brand name Duexis. This drug combination is indicated for the management of symptoms associated with rheumatoid arthritis and osteoarthritis, while also minimizing the risk of upper gastrointestinal ulcers in patients taking ibuprofen for these conditions.
• Also in February 2025, Aurora Pharmaceutical (Private) introduced EquiCoxib, its FDA-approved generic version of Equioxx® (firocoxib)-a non-steroidal anti-inflammatory drug (NSAID) designed to relieve pain and inflammation due to osteoarthritis
• In January 2025, NEXTBIOMEDICAL CO., LTD, a KOSDAQ-listed innovative medical device company in South Korea, proudly announced that it has received Investigational Device Exemption (IDE) approval from the U.S. Food and Drug Administration (FDA) for its clinical trial, named "RESORB", featuring Nexsphere-FTM. Designed to alleviate pain in knee osteoarthritis patients, the fast resorbable embolic microsphere will undergo a multi-center trial in the United States for market approval, marking a significant milestone in its global expansion strategy.
• On November 12, 2024, Genascence Corporation (Private)-a clinical-stage biotech company specializing in gene therapy for musculoskeletal disorders-announced that the FDA has granted Fast Track Designation (FTD) to GNSC-001, a novel gene therapy candidate currently under development for treating knee osteoarthritis.
• In December 2023, Bioventus agreed to a nationwide contract with Aetna Medicare Advantage plans. Beginning January 1, 2024, over 3 million Aetna Medicare Advantage plan members will have access to DUROLANE to treat knee osteoarthritis pain.
• In December 2023, Levicept announced that it had completed recruitment in its Phase II clinical trial of LEVI-04, a novel neurotrophin-modulating biological agent. Top-line data are expected to be announced in the late first half of 2024.
• In Jan 2023, OliPass Corporation announced a study which is designed to evaluate the efficacy, safety and tolerability of OLP-1002 Subcutaneous (SC) injections for reducing moderate to severe pain due to osteoarthritis in a hip and/or knee joint.

Osteoarthritis Overview
Osteoarthritis is a chronic degenerative joint disease characterized by the progressive breakdown of cartilage, leading to joint pain, stiffness, and reduced mobility. Osteoarthritis symptoms typically include swelling, tenderness, and a grating sensation during joint movement. Osteoarthritis causes are multifactorial, involving aging, genetic predisposition, obesity, previous joint injuries, and repetitive stress on the joints. Osteoarthritis pathophysiology centers on cartilage degradation, subchondral bone remodeling, synovial inflammation, and formation of osteophytes, collectively worsening joint integrity.

Osteoarthritis diagnosis relies on clinical assessment, patient history, physical examination, and imaging techniques like X-rays and MRI to evaluate joint space narrowing and bone changes. Osteoarthritis treatment encompasses lifestyle modifications, weight management, physiotherapy, analgesics, NSAIDs, intra-articular injections, and in severe cases, joint replacement surgery. Osteoarthritis management strategies aim to reduce pain, maintain joint function, and improve quality of life. Osteoarthritis research is actively exploring disease-modifying therapies, regenerative medicine, and novel biologics to slow disease progression.

Osteoarthritis prevalence increases with age, making it the most common form of arthritis globally. Osteoarthritis burden significantly impacts healthcare systems due to disability and reduced work productivity. Osteoarthritis awareness and early interventions are essential to mitigate complications and enhance long-term outcomes.

Get a Free Sample PDF Report to know more about Osteoarthritis Pipeline Therapeutic Assessment- https://www.delveinsight.com/sample-request/osteoarthritis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Osteoarthritis Route of Administration
Osteoarthritis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Osteoarthritis Molecule Type
Osteoarthritis Products have been categorized under various Molecule types, such as
• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Osteoarthritis Pipeline Therapeutics Assessment
• Osteoarthritis Assessment by Product Type
• Osteoarthritis By Stage and Product Type
• Osteoarthritis Assessment by Route of Administration
• Osteoarthritis By Stage and Route of Administration
• Osteoarthritis Assessment by Molecule Type
• Osteoarthritis by Stage and Molecule Type

DelveInsight's Osteoarthritis Pipeline Report covers around 110+ products under different phases of clinical development like-
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Osteoarthritis product details are provided in the report. Download the Osteoarthritis pipeline report to learn more about the emerging Osteoarthritis therapies- https://www.delveinsight.com/report-store/osteoarthritis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Osteoarthritis Pipeline Analysis:
The Osteoarthritis pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Osteoarthritis with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Osteoarthritis Treatment.
• Osteoarthritis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Osteoarthritis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Osteoarthritis market.

Download Sample PDF Report to know more about Osteoarthritis drugs and therapies- https://www.delveinsight.com/sample-request/osteoarthritis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Scope of Osteoarthritis Pipeline Drug Insight
• Coverage: Global
• Osteoarthritis companies: Biosplice Therapeutics, Cynata Therapeutics, Bone Therapeutics S.A, Regeneron Pharmaceuticals, Techfields Pharma, Ampio Pharmaceuticals, Asahi Kasei Pharma, Taiwan Bio Therapeutics, OliPass Corporation, Bioventus, Medipost, LG Chem, ICM Biotech, Cells for Cells SA, GWOXI Stem Cell Applied Technology, UnicoCell Biomed, Magellan Biologicals, Levicept, Arthrogen, Personalized Stem Cells, Peptinov, Orient Europharma, ZYUS Life Sciences, Lubris Biopharma, Saol Therapeutics, Ageless Biotech, Synartro AB, Plakous Therapeutics, Ribomic, Meluha Therapeutics, and others.
• Osteoarthritis therapies: Lorecivivint, EP-104IAR, DFV890, 4P004, GNSC 001, and others.
• Osteoarthritis Therapeutic Assessment: Osteoarthritis current marketed and Osteoarthritis emerging therapies
• Osteoarthritis Market Dynamics: Osteoarthritis market drivers and Osteoarthritis market barriers

Request for Sample PDF Report for Osteoarthritis Pipeline Assessment and clinical trials - https://www.delveinsight.com/sample-request/osteoarthritis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Table of Contents
1. Osteoarthritis Report Introduction
2. Osteoarthritis Executive Summary
3. Osteoarthritis Overview:
4. Osteoarthritis- Analytical Perspective In-depth Commercial Assessment
5. Osteoarthritis Pipeline Therapeutics
6. Osteoarthritis Late Stage Products (Phase II/III)
7. Osteoarthritis Mid Stage Products (Phase II)
8. Osteoarthritis Early Stage Products (Phase I)
9. Osteoarthritis Preclinical Stage Products
10. Osteoarthritis Therapeutics Assessment
11. Osteoarthritis Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Osteoarthritis Companies
14. Osteoarthritis Key Products
15. Osteoarthritis Unmet Needs
16 . Osteoarthritis Market Drivers and Barriers
17. Osteoarthritis Future Perspectives and Conclusion
18. Osteoarthritis Analyst Views
19. Appendix
20. About DelveInsight

Related Reports:
Osteoarthritis Epidemiology
https://www.delveinsight.com/report-store/osteoarthritis-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Osteoarthritis Epidemiology Forecast - 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, and the osteoarthritis epidemiology trends.

Osteoarthritis Pipeline
https://www.delveinsight.com/report-store/osteoarthritis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Osteoarthritis Pipeline Insight - 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key osteoarthritis companies, including Biosplice Therapeutics, Cynata Therapeutics, Bone Therapeutics S.A, Regeneron Pharmaceuticals, Techfields Pharma, Ampio Pharmaceuticals, Asahi Kasei Pharma, Taiwan Bio Therapeutics, OliPass Corporation, Bioventus, Medipost, LG Chem, ICM Biotech, Cells for Cells SA, GWOXI Stem Cell Applied Technology, UnicoCell Biomed, Magellan Biologicals, Levicept, Arthrogen, Personalized Stem Cells, Peptinov, Orient Europharma, ZYUS Life Sciences, Lubris Biopharma, Saol Therapeutics, Ageless Biotech, Synartro AB, Plakous Therapeutics, Ribomic, Meluha Therapeutics, among others.

Knee Osteoarthritis Market
https://www.delveinsight.com/report-store/knee-osteoarthritis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Knee Osteoarthritis Market Insights, Epidemiology, and Market Forecast - 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key knee osteoarthritis companies, including Centrexion Therapeutics, Pfizer, Eli Lilly, Ampio Pharmaceuticals, Galapagos NV, Cytonics, Flexion Therapeutics, among others.

Erosive Hand Osteoarthritis Market
https://www.delveinsight.com/report-store/erosive-hand-osteoarthritis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Erosive Hand Osteoarthritis Market Insights, Epidemiology, and Market Forecast - 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key erosive hand osteoarthritis companies, including AbbVie, Celgene Corporation, Amgen, XOMA (US) LLC, among others.

Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679
https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

This release was published on openPR.